SAN DIEGO, Aug. 10, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and six-months ended June 30, 2017, and provides an update on its business progress.
"Our positive second quarter 2017 financial results reflect the Company's focus on increasing sales force productivity, refreshing our marketing message, and improving collections from third-party health plans to accelerate growth of our revenue and test volume," said Michael Nall, President and CEO of Biocept. "In early June at the American Society of Clinical Oncology annual meeting, we launched the 'AND' marketing campaign that highlights the advantages of combining liquid biopsy and tissue biopsy for patients with metastatic non-small cell lung cancer (NSCLC). To date, we've received a positive reception from physicians to this campaign, given the potential to qualify more cancer patients for targeted therapy in the first-line setting using Biocept's liquid biopsy platform.
"Our positive second quarter 2017 financial results reflect the Company's focus on increasing sales force productivity, refreshing our marketing message, and improving collections from third-party health plans to accelerate growth of our revenue and test volume," said Michael Nall, President and CEO of Biocept. "In early June at the American Society of Clinical Oncology annual meeting, we launched the 'AND' marketing campaign that highlights the advantages of combining liquid biopsy and tissue biopsy for patients with metastatic non-small cell lung cancer (NSCLC). To date, we've received a positive reception from physicians to this campaign, given the potential to qualify more cancer patients for targeted therapy in the first-line setting using Biocept's liquid biopsy platform.
